Abstracts tagged "Epidemiology"

Abstract Number: 0756 • ACR Convergence 2022
Rheumatic Toxicities of Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and the Effect of Pre-existing Autoimmune and Non-immune Mediated Rheumatic Conditions
Alana Bruce¹, Georgina V Long², Alexander M Menzies², Brian Fernandes³ and Fredrick Joshua⁴, ¹Macquarie University, Balaclava, Victoria, Australia, ²Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia, ³Royal Prince Alfred Hospital, Sydney, Australia, ⁴Macquarie University, Integrated Specialist Medical Care, Sydney, Australia
Background/Purpose: To estimate the frequency of rheumatic toxicities of immune checkpoint inhibitors (ICI) presenting as de novo or exacerbations of pre-existing rheumatic disease in patients…
Abstract Number: 1186 • ACR Convergence 2022
The Trajectory of Multimorbidity in Patients with Systemic Lupus Erythematosus in the United States
Ali Duarte-Garcia¹, Maria Stevens², Herbert Heien², Gabriel Figueroa Parra¹, Jose A Meade-Aguilar¹, Molly M. Jeffery², Uma Thanarajasingam¹, Cynthia Crowson³ and Rozalina McCoy², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Eyota, MN
Background/Purpose: The presence of multiple chronic conditions (multimorbidity) is associated with disability and premature death. We determined the trajectory of multimorbidity in SLE compared to…
Abstract Number: 1278 • ACR Convergence 2022
ANA Testing Practices in the United States: A Population-Based Study Between 2000 and 2019
Mehmet Hocaoglu¹, Alain Sanchez-Rodriguez², Hannah Langenfeld³, Cynthia Crowson⁴ and Ali Duarte-Garcia⁵, ¹University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ²Division of Rheumatology, Mayo Clinic, Rochester, MN, ³Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Eyota, MN, ⁵Mayo Clinic, Rochester, MN
Background/Purpose: Inappropriate laboratory testing accounts for an important part of avoidable healthcare costs. Anti-nuclear antibody (ANA) is a commonly used laboratory test in rheumatology with…
Abstract Number: 1612 • ACR Convergence 2022
Prediction of Psoriatic Arthritis Tool (PRESTO): Development and Performance of a New Scoring System for Psoriatic Arthritis Risk
Lihi Eder¹, Ker-Ai Lee², Vinod Chandran³, Jessica Widdifield⁴, Aaron Drucker⁴, Christopher Ritchlin⁵, Cheryl F Rosen⁴, Richard Cook² and Dafna Gladman⁶, ¹Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁶Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: A simple, scalable tool that identifies psoriasis patients at high risk for developing PsA could improve early detection and facilitate early intervention. Our overall…
Abstract Number: 1773 • ACR Convergence 2022
Epidemiology and Outcomes of Raynaud’s Phenomenon Hospitalizations in the US
Rashmi Dhital¹, Monica Guma², Thuthiri Lwin³, Amar Suwal⁴ and Brian Pedersen¹, ¹UC San Diego, San Diego, CA, ²UCSD, La Jolla, CA, ³University of California San Diego, San Diego, CA, ⁴Reading Hospital, Tower Health, Reading, PA
Background/Purpose: The prevalence of Raynaud's phenomenon (RP) in the general population is ~3-5%, of which 80–90% are primary. Autoimmune diseases are the most common causes…
Abstract Number: 2073 • ACR Convergence 2022
The Incidence of COVID-19 Infection in an SLE Cohort, and Its Association with Immunosuppressants, SLE Disease Activity, Vaccination Status, and COVID-19 Antibodies
Laurence S Magder¹, Andrea Fava², Daniel W. Goldman³ and Michelle Petri³, ¹University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: An important clinical question is whether treatments (e.g, corticosteroids, immunosuppressants) or SLE disease activity are associated with an increased risk of COVID-19 infection among…
Abstract Number: 0302 • ACR Convergence 2022
Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis
SE RIM CHOI¹, Anna Shin², You-Jung Ha², Yun Jong Lee², Eun Bong Lee¹ and Eun Ha Kang², ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Seoul National University Bundang Hospital, Seongnam, Republic of Korea
Background/Purpose: To compare infectious risk between JAK inhibitors (JAKi) versus TNF inhibitors (TNFi) among patients with rheumatoid arthritis (RA) in Korea. Methods: Using 2009-2019 Korea…
Abstract Number: 0553 • ACR Convergence 2022
Stair Climbing Difficulty and Risk of Functional Limitation in Knee Osteoarthritis: A Simple Functional Vital Sign?
Jason Jakiela¹, Dana Voinier¹, Yvonne Golightly², Jennifer Horney¹, Thomas Bye¹, Jéssica Bianca Aily¹ and Daniel White¹, ¹University of Delaware, Newark, DE, ²University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Knee osteoarthritis (OA) is a leading cause of functional limitation in older adults, and difficulty with climbing stairs is often the first-reported limitation. As…
Abstract Number: 0772 • ACR Convergence 2022
New Onset Rheumatologic Syndromes After Covid-19 Vaccination: Systematic Review
Carina Soto-Fajardo¹, Angélica Peña Ayala², Fernanda Gonzalez², Paola Flores², Ana Cristina Medina², Araceli Bernal², Carlos Pineda², Olga-Lidia Vera-Lastra³ and Luis Javier Jara Quezada², ¹Instituto Nacional de Rehabilitacion "Luis Guillermo Ibarra Ibarra", Ciudad de México, Mexico, ²Instituto Nacional de Rehabilitacion, Ciudad de México, Mexico, ³Centro Médico La Raza, Ciudad de México, Mexico
Background/Purpose: From January 2021 around 60% of the total population has received at least one dose of any COVID-19 vaccine. A minority of vaccinated individuals…
Abstract Number: 1190 • ACR Convergence 2022
Multimorbidity in Systemic Sclerosis: Burden and Trends in Prevalence from an Incident Population-based Cohort (1980-2018)
Ashima Makol¹, Sara Achenbach¹, Alicia Hinze², Tina Gunderson³ and Cynthia Crowson⁴, ¹Mayo Clinic, Rochester, MN, Rochester, MN, ²Mayo Clinic - Rochester, MN, Rochester, MN, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Eyota, MN
Background/Purpose: To estimate the prevalence and trends of multimorbidity (MM; the presence of ≥2 morbidities) in a population-based cohort of patients with Systemic sclerosis (SSc)…
Abstract Number: 1316 • ACR Convergence 2022
A Cluster of Paget Disease of the Bone in Black or African American Patients in a Veteran Population
Mariana Urquiaga and Angelo Gaffo, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Genetic and environmental factors have been implicated in the pathogenesis of Paget Disease of the Bone (PDB). Although the disease is described more frequently…
Abstract Number: 1615 • ACR Convergence 2022
Myocardial Infarction in Patients with Systemic Vasculitis and Population Controls: Characteristics and Overall Mortality
Pavlos Stamatis¹, Moman Mohammad², David Erlinge², Carl Turesson³, David Jayne⁴ and Aladdin Mohammad⁵, ¹Department of Clinical Sciences Lund, Rheumatology, Lund University, Sweden, Larissa, Larisa, Greece, ²Department of Clinical Sciences Lund, Cardiology, Lund University, Lund, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴University of Cambridge, Cambridge, United Kingdom, ⁵Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden
Background/Purpose: The deleterious effect of inflammation combined with glucocorticoid treatment may increase the risk for atherosclerotic events. The aims of this study were to investigate…
Abstract Number: 1774 • ACR Convergence 2022
Performance of an Early Triage System for Identification of Patients with Inflammatory Rheumatic Diseases
Xenofon Baraliakos¹, Imke Redeker², Maria Zacharopoulou², Styliani Tsiami³ and Juergen Braun⁴, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Ruhr-University Bochum, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: The preselection of patients with suspicion of an inflammatory rheumatic disease is not easy for general practitioners and orthopedists. In countries with a limited…
Abstract Number: 2075 • ACR Convergence 2022
Risk of Bloodstream Infection in Patients with Systemic Lupus Erythematosus Exposed to Prolonged Moderate to High Dose Glucocorticoids
MI HYEON KIM¹, Eun Bong Lee¹, Eun Young Lee², Jin Kyun Park³ and Jun Won Park¹, ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Seoul National University College of Medicine, Seoul, Republic of Korea, ³Seoul National University College of Medicine, Jongno-gu, Seoul, South Korea
Background/Purpose: This study aimed to investigate the incidence and risk factors of bloodstream infection (BSI) in patients with systemic lupus erythematosus (SLE) receiving moderate-to-high dose…
Abstract Number: 0334 • ACR Convergence 2022
Performance of Diagnosis Codes for Identification of Prevalent Lupus Nephritis Patients from Electronic Health Records
Zara Izadi¹, Alfredo Aguirre², Christine Anastasiou², Julia Kay³, Gabriela Schmajuk⁴ and Jinoos Yazdany⁵, ¹University of California San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³UCSF, San Francisco, CA, ⁴UCSF / SFVA, San Francisco, CA, ⁵UCSF, San Rafael, CA
Background/Purpose: Real-world data could provide valuable information in the study of lupus nephritis (LN), if these cases could be reliably identified. A lack of ability…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].